Exchange: NASDAQ·Updated 06:03 PM EDT
DRTS logo

DRTSALPHA TAU MEDICAL LTD

$12.70
$0.025
(0.20%)
Today
Closed $12.78
$0.08
(0.63%)
After Hours
EarningsAug 10
Mkt Cap$1.12B
Vol547,171.00
News
all
press releases
New Strong Sell Stocks for July 7th
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
Zacks
News Placeholder
More News
News Placeholder
New Strong Sell Stocks for July 2nd
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Zacks
News Placeholder
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic...
PR Newswire
News Placeholder
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing
Alpha Tau signed an agreement with Tolmar to commercialize its lead cancer therapy for prostate cancer in the United States.
Stocktwits
News Placeholder
DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week
An extract featuring safety and efficacy results from three studies evaluating its key therapy for pancreatic cancer will be unveiled on Thursday.
Stocktwits
News Placeholder
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
Alpha Tau Medical stock surged after interim glioblastoma data showed complete responses in two patients treated with Alpha DaRT.read more...
Benzinga
News Placeholder
DRTS Stock Surges Pre-Market Even As Retail Traders Debate ‘Too Small’ Brain Cancer Trial Data
The biotech company’s experimental treatment for recurrent glioblastoma resulted in complete responses in 2 of the first 3 patients.
Stocktwits
News Placeholder
Nasdaq, S&P 500 Futures Dip As Trump-Iran Tensions Lift Crude Oil Prices: Why MU, MRAM, MLTX, DRTS, ASTS Are In Focus
Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ, following last week’s resilience in tech and AI-linked names.
Stocktwits
News Placeholder
DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today
Last week, Alpha Tau Medical completed enrollment in its ReStart study for recurring skin cancer.
Stocktwits
News Placeholder
Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Still a Buy?
Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's Why...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.